Our previous investigation on alkylaminophenols such as THTMP, THMPP, and HNPMI as effective inhibitors of EGFR has been reported against breast cancer, glioblastoma, and osteosarcoma (Doan et al., 2016b; Nguyen et al., 2021; Palanivel et al., 2020), which motivated us to unravel its potential against CRC. Here, EGFR is linked to breast cancer.